^
Association details:
| Biomarker: | CD22 positive |
|---|---|
| Cancer: | T Cell Non-Hodgkin Lymphoma |
| Drug: | TRPH-222 (Microtubule inhibitor, CD22-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
CAT-02-106, a Site-Specifically Conjugated Anti-CD22 Antibody Bearing an MDR1-Resistant Maytansine Payload Yields Excellent Efficacy and Safety in Preclinical Models
Excerpt:
An opportunity exists for a next-generation anti-CD22 antibody–drug conjugate (ADC) to address unmet medical needs in the relapsed/refractory NHL population. We describe a site-specifically conjugated antibody–drug conjugate, made using aldehyde tag technology, targeted against CD22 and bearing a noncleavable maytansine payload that is resistant to MDR1-mediated efflux. The construct was efficacious against CD22+ NHL xenografts...Together, the data suggest that this drug has the potential to be used effectively in patients with CD22+ tumors that have developed MDR1-related resistance to prior therapies.
DOI:
https://doi.org/10.1158/1535-7163.MCT-17-0776
